BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

351 related articles for article (PubMed ID: 18165618)

  • 1. Elderly cancer patients receiving chemotherapy benefit from first-cycle pegfilgrastim.
    Balducci L; Al-Halawani H; Charu V; Tam J; Shahin S; Dreiling L; Ershler WB
    Oncologist; 2007 Dec; 12(12):1416-24. PubMed ID: 18165618
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Risk of hospitalization for neutropenic complications of chemotherapy in patients with primary solid tumors receiving pegfilgrastim or filgrastim prophylaxis: a retrospective cohort study.
    Weycker D; Malin J; Kim J; Barron R; Edelsberg J; Kartashov A; Oster G
    Clin Ther; 2009 May; 31(5):1069-81. PubMed ID: 19539108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Neutropenic events in community practices reduced by first and subsequent cycle pegfilgrastim use.
    Ozer H; Mirtsching B; Rader M; Luedke S; Noga SJ; Ding B; Dreiling L
    Oncologist; 2007 Apr; 12(4):484-94. PubMed ID: 17470691
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pegfilgrastim administered on the same day with dose-dense adjuvant chemotherapy for breast cancer is associated with a higher incidence of febrile neutropenia as compared to conventional growth factor support: matched case-control study of the Hellenic Cooperative Oncology Group.
    Skarlos DV; Timotheadou E; Galani E; Samantas E; Grimani I; Lianos E; Aravantinos G; Xanthakis I; Pentheroudakis G; Pectasides D; Fountzilas G
    Oncology; 2009; 77(2):107-12. PubMed ID: 19622901
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Safety and efficacy of pegfilgrastim in children with cancer receiving myelosuppressive chemotherapy.
    André N; Kababri ME; Bertrand P; Rome A; Coze C; Gentet JC; Bernard JL
    Anticancer Drugs; 2007 Mar; 18(3):277-81. PubMed ID: 17264759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Granulocytic growth factors and cancer-related neutropenia: limited effects.
    Prescrire Int; 2006 Oct; 15(85):189-91. PubMed ID: 17128529
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer.
    Siena S; Piccart MJ; Holmes FA; Glaspy J; Hackett J; Renwick JJ
    Oncol Rep; 2003; 10(3):715-24. PubMed ID: 12684649
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Comparison of hospitalization risk and associated costs among patients receiving sargramostim, filgrastim, and pegfilgrastim for chemotherapy-induced neutropenia.
    Heaney ML; Toy EL; Vekeman F; Laliberté F; Dority BL; Perlman D; Barghout V; Duh MS
    Cancer; 2009 Oct; 115(20):4839-48. PubMed ID: 19637341
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of pegfilgrastim with filgrastim on febrile neutropenia, grade IV neutropenia and bone pain: a meta-analysis of randomized controlled trials.
    Pinto L; Liu Z; Doan Q; Bernal M; Dubois R; Lyman G
    Curr Med Res Opin; 2007 Sep; 23(9):2283-95. PubMed ID: 17697451
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pegfilgrastim dosing on same day as myelosuppressive chemotherapy for ovarian or primary peritoneal cancer.
    Schuman SI; Lambrou N; Robson K; Glück S; Myriounis N; Pearson JM; Lucci JA
    J Support Oncol; 2009; 7(6):225-8. PubMed ID: 20380330
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative effectiveness of filgrastim, pegfilgrastim, and sargramostim as prophylaxis against hospitalization for neutropenic complications in patients with cancer receiving chemotherapy.
    Weycker D; Malin J; Barron R; Edelsberg J; Kartashov A; Oster G
    Am J Clin Oncol; 2012 Jun; 35(3):267-74. PubMed ID: 21378538
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dose intensity and hematologic toxicity in older cancer patients receiving systemic chemotherapy.
    Shayne M; Culakova E; Poniewierski MS; Wolff D; Dale DC; Crawford J; Lyman GH
    Cancer; 2007 Oct; 110(7):1611-20. PubMed ID: 17705197
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pegfilgrastim supports delivery of FEC-100 chemotherapy in elderly patients with high risk breast cancer: a randomized phase 2 trial.
    Romieu G; Clemens M; Mahlberg R; Fargeot P; Constenla M; Schütte M; Easton V; Skacel T; Bacon P; Brugger W
    Crit Rev Oncol Hematol; 2007 Oct; 64(1):64-72. PubMed ID: 17317205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pegfilgrastim after high-dose chemotherapy and autologous peripheral blood stem cell transplant: phase II study.
    Jagasia MH; Greer JP; Morgan DS; Mineishi S; Kassim AA; Ruffner KL; Chen H; Schuening FG
    Bone Marrow Transplant; 2005 Jun; 35(12):1165-9. PubMed ID: 15880129
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A pharmacokinetic and dose escalation study of pegfilgrastim (KRN125) in lung cancer patients with chemotherapy-induced neutropenia.
    Yamamoto N; Sekine I; Nakagawa K; Takada M; Fukuoka M; Tanigawara Y; Saijo N
    Jpn J Clin Oncol; 2009 Jul; 39(7):425-30. PubMed ID: 19395467
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of febrile neutropenia in breast cancer patients receiving epirubicin and docetaxel/paclitaxel with colony-stimulating growth factors: a comparison of filgrastim or lenograstim with pegfilgrastim.
    Schippinger W; Holub R; Dandachi N; Bauernhofer T; Samonigg H
    Oncology; 2006; 70(4):290-3. PubMed ID: 16899982
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pegfilgrastim for chemotherapy-induced neutropenia.
    Bedell C
    Clin J Oncol Nurs; 2003; 7(1):55-6, 63-4. PubMed ID: 12629935
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effectiveness of colony-stimulating factors for febrile neutropenia: a retrospective study.
    Tan H; Tomic K; Hurley D; Daniel G; Barron R; Malin J
    Curr Med Res Opin; 2011 Jan; 27(1):79-86. PubMed ID: 21091127
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cost-effectiveness of pegfilgrastim versus filgrastim primary prophylaxis in women with early-stage breast cancer receiving chemotherapy in the United States.
    Lyman GH; Lalla A; Barron RL; Dubois RW
    Clin Ther; 2009 May; 31(5):1092-104. PubMed ID: 19539110
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Targeted filgrastim support in patients with early-stage breast carcinoma: toward the implementation of a risk model.
    Rivera E; Erder MH; Moore TD; Shiftan TL; Knight CA; Fridman M; Brannan C; Danel-Moore L; Hortobagyi GN;
    Cancer; 2003 Jul; 98(2):222-8. PubMed ID: 12872339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.